Repeated Stereotactic Radiotherapy for Local Brain Metastases Failure or Distant Brain Recurrent: A Retrospective Study of 184 Patients.
Fiche publication
Date publication
octobre 2023
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine, Pr NOEL Georges, Dr CEBULA Hélène, Dr LE FEVRE Clara
Tous les auteurs :
Kuntz L, Le Fèvre C, Jarnet D, Keller A, Meyer P, Mazzara C, Cebula H, Noel G, Antoni D
Lien Pubmed
Résumé
The main advantages of stereotactic radiotherapy (SRT) are to delay whole-brain radiotherapy (WBRT) and to deliver ablative doses. Despite this efficacy, the risk of distant brain metastases (BM) one year after SRT ranges from 26% to 77% and 20 to 40% of patients required salvage treatment. The role and consequences of reirradiation remain unclear, particularly in terms of survival. The objective was to study overall survival (OS) and neurological death-free survival (NDFS) and to specify the prognostic factors of long-term survival.
Mots clés
brain metastases, oligorecurrence, radiotherapy, reirradiation, repeated radiosurgery, salvage radiation, stereotactic radiosurgery
Référence
Cancers (Basel). 2023 10 11;15(20):